2022 Genitourinary Cancers Symposium
The 2022 Genitourinary Cancers Symposium publication includes articles and expert perspectives on the groundbreaking data presented at the 2022 Genitourinary Cancers Symposium in San Francisco, California.
Volume: 01
Issue: 01
2021 ESMO Congress: Genitourinary Cancers
The 2021 ESMO Congress priority report focuses on updates in genitourinary cancers presented at the virtual conference, held September 16 to 21, 2021.
Volume: 1
Issue: 1
ASCO 2021: Updates in Genitourinary Cancers
This publication provides coverage of data in genitourinary cancers that were presented at the 2021 ASCO Annual Meeting.
2021 Genitourinary Cancers Symposium
Volume: 02
ASCO 2020: Update on Genitourinary Cancers
2020 Genitourinary Cancers Symposium
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer